Q1 tells a story of deliberate value accumulation. The 65% stake increase in Teva — buying an Israel-based generic pharma at depressed prices while peers panicked — is classic Druckenmiller: enter when the narrative is broken, not when it's confirmed. Simultaneously, he trimmed Philip Morris and began reducing cyclicals. The portfolio shrank to $3.06B (from a higher Q4 2024 base), suggesting some risk-off repositioning. Biotech remains the conviction core — NTRA at 15.7% of the portfolio signals a multi-year thesis, not a trade. The cyclical exits (UAL, Seagate) confirm he was not yet positioned for a broad economic reopening.

Q2 is the most structurally interesting quarter of the year. 35 new positions in a single quarter is extraordinary for a concentrated macro investor. Entegris (chip materials), Microsoft (re-entry), Sea Limited (SEA digital economy), and Citigroup (financials) were all initiated. The breadth of these bets — spanning tech supply chain, enterprise SaaS, emerging markets, and US financials — looks like a man who sees a regime change coming but doesn't yet know which legs of the trade will dominate. In retrospect, the Citigroup initiation (later exited in Q4 in favor of XLF) and Entegris (doubled down in Q4) were early prototypes of the final Q4 thesis. Druckenmiller was stress-testing ideas he would either scale or abandon over the next two quarters.

Q3 marks peak biotech concentration. NTRA, INSM, and TEVA combined exceeded 30% of the entire portfolio — an extraordinary bet for a macro investor managing a multi-billion dollar family office. NTRA alone approached $741M in value. The Amazon and Meta initiations in Q3 appear to test whether AI platform plays belong in the book. By Q4, Meta was fully exited after one quarter — the thesis played out quickly. Amazon was kept and aggressively added (+69%). The divergence reveals Druckenmiller's actual conviction: cloud infrastructure (AWS) yes, social media AI adjacency (Meta) no. The Eli Lilly exit also matters — it signals the pharma thesis is company-specific (Teva's generic recovery, INSM's pipeline), not a sector call on biotech broadly.

Q4 2025 is the culmination of a year-long repositioning. The $301M XLF buy — the single largest new position — paired with the simultaneous exits of Bank of America and Citigroup, reveals a deliberate move from single-name bank exposure to sector-wide deregulation. The $247M EWZ (Brazil ETF) and continued building of Coupang and Sea Limited construct a coherent EM recovery thesis premised on a softer dollar. The $225M RSP (equal-weight S&P) is Druckenmiller explicitly betting against Magnificent-7 dominance. The Bloom Energy initiation (fuel cells for data centers) alongside the EQT exit (nat gas) completes a clean energy-of-AI trade rotation. And the ARM exit — despite his AI infrastructure thesis — confirms he exits on valuation, not narrative. The 13F was filed February 17, 2026, eighteen days after the Warsh nomination. The Q4 positioning had already been set. The receipts confirm the anticipation.